title: Immunotherapy and Oncogenic Pathways: The PTEN Connection.
abstract: Peng and colleagues describe the effects of PTEN inactivation on antitumor immunity and response to immune checkpoint blockade in melanoma. These results shed light on the intricate interplay between oncogenic pathways and antitumor immune response.
authors: Division of Hematology and Oncology, Columbia University/New York Presbyterian Hospital, New York, New York.
authors: Naiyer A
authors: NA
authors: Rizvi
authors: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. chant@mskcc.org.
authors: Timothy A
authors: TA
authors: Chan
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D009154:Mutation; D009362:Neoplasm Metastasis; D051059:PTEN Phosphohydrolase / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human